Imugene’s Azer-cel Earns Rare Oral Slot at ASCO From 8,500+ Submissions

Imugene’s azer-cel earns oral presentation slot at ASCO 2026 from 8,500+ submissions

Imugene (ASX: IMU) has reported that azer-cel clinical data was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation slot, a distinction awarded to only a small proportion of the more than 8,500 abstracts submitted to the world’s leading oncology conference. The presentation was delivered by Dr Supriya Gupta from the University of Minnesota during the Oral Abstract Session on Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia on 29 May 2026 at 1:00 PM CDT.

ASCO’s peer-reviewed Scientific Program Committee selects oral presentations based on clinical significance and scientific quality, positioning azer-cel among the most significant data readouts at a conference that attracts more than 40,000 oncology professionals, researchers, and investors annually. Oral selection signals peer-reviewed scientific credibility — this is a platform presentation to the global oncology community, not a poster in a back hall.

Response rates across six blood cancer subtypes

The Phase 1b clinical data presented at ASCO covered the CAR-T naïve cohort, in which 25 patients with relapsed or refractory CD19-positive B-cell malignancies received azer-cel (azercabtagene zapreleucel) in combination with low-dose IL-2. Of these, 24 patients were evaluable for response at their first disease assessment on Day 28. Responses were observed across all six cancer subtypes tested, demonstrating breadth of activity.

Consistent responses across multiple subtypes suggest potential for broad label applications in CD19-positive B-cell malignancies, positioning azer-cel as a multi-indication asset rather than a single-disease therapy. The data represents early-stage efficacy signals from a CAR-T naïve patient population, with further follow-up expected to assess durability.

What is azer-cel and why does “allogeneic” matter?

Azer-cel is an allogeneic (off-the-shelf) CAR-T therapy targeting CD19, a protein found on B-cell blood cancers. The allogeneic designation has significant implications for manufacturing and patient access:

• Autologous CAR-T: Requires harvesting a patient’s own immune cells, manufacturing a personalised product, and waiting weeks for delivery. The process is resource-intensive and patient-specific.

• Allogeneic CAR-T: Pre-manufactured from donor cells and available off-the-shelf. Patients can receive treatment without delay, and the product can be manufactured at scale.

Off-the-shelf CAR-T has manufacturing and cost-of-goods advantages that could improve commercial scalability and patient access, particularly in healthcare systems where autologous CAR-T infrastructure is limited. For investors, the allogeneic model represents a pathway to broader market penetration compared to personalised cell therapies.

Trial expansion into Cohort 3 with BTK inhibitor combination

The Phase 1b azer-cel study has expanded into Cohort 3, which evaluates azer-cel in concurrent dosing with Bruton Tyrosine Kinase inhibitors (BTKi). The first patient in Cohort 3 was dosed on 28 May 2026, one day before the ASCO presentation, signalling operational momentum as the trial progresses.

The multi-cohort study is now active across 10 US sites and 5 Australian sites, enrolling patients with relapsed or refractory CD19-positive B-cell malignancies. Existing cohorts include CAR-T naïve patients (the cohort presented at ASCO) and CAR-T relapsed/refractory patients, allowing the trial to evaluate azer-cel across different treatment histories.

Combination strategies with BTKi could address durability and resistance challenges observed in earlier-generation CAR-T therapies. BTK inhibitors are standard-of-care treatments for several B-cell malignancies, and concurrent dosing may enhance CAR-T persistence or overcome resistance mechanisms. Cohort 3 dosing immediately before ASCO suggests the company is advancing its development programme while clinical interest remains high.

CEO commentary on clinician engagement

Leslie Chong, Managing Director and CEO

“The level of interest and depth of questioning from clinicians and researchers at our oral presentation at ASCO was genuinely encouraging. These are some of the most rigorous scientific minds in oncology, and the engagement we saw reflects growing recognition of azer-cel and its potential to offer patients further treatment options. We look forward to providing further updates as the data matures.”

Clinician engagement at ASCO serves as a qualitative validation beyond the peer-reviewed abstract process. Questions from oncologists and researchers at a platform presentation often indicate interest in trial participation, patient referrals, or future adoption, making floor-level engagement a forward indicator of commercial potential.

What investors should watch next

Near-term catalysts for Imugene’s azer-cel programme include:

• Data maturation: Management has flagged further updates as the data matures. Investors should monitor for durability readouts and longer-term follow-up from the CAR-T naïve cohort, particularly progression-free survival and overall survival metrics.

• Cohort 3 progression: Early safety and efficacy signals from the BTKi combination dosing cohort will indicate whether concurrent therapy enhances response rates or durability.

• Regulatory pathway discussions: ASCO visibility often precedes regulatory interactions with agencies such as the US Food and Drug Administration or Australia’s Therapeutic Goods Administration. Potential for expedited designation discussions (e.g., Breakthrough Therapy Designation) could emerge if durability data supports a favourable benefit-risk profile.

• Trial site expansion: Additional sites in the US or internationally could accelerate enrolment and diversify the patient population.

The full abstract is available at asco.org/abstracts, and the ASCO presentation is accessible at imugene.com/investors/conference-presentations. These materials provide technical detail on response criteria, dosing schedules, and trial design for readers seeking further clinical depth.

Want to Track Imugene’s Azer-Cel Programme as New Data Emerges?

With Cohort 3 now dosing and durability readouts expected from the CAR-T naïve cohort, azer-cel’s development timeline is accelerating. ASCO visibility often precedes regulatory discussions, and early combination data could reshape the commercial profile of this allogeneic platform.

Investors monitoring regulatory catalysts, trial site expansion, or potential Breakthrough Therapy Designation discussions can access the full abstract and trial updates via the Imugene investor centre. Management has flagged further announcements as the data matures—staying informed now positions you ahead of material readouts.